<code id='0786A91E31'></code><style id='0786A91E31'></style>
    • <acronym id='0786A91E31'></acronym>
      <center id='0786A91E31'><center id='0786A91E31'><tfoot id='0786A91E31'></tfoot></center><abbr id='0786A91E31'><dir id='0786A91E31'><tfoot id='0786A91E31'></tfoot><noframes id='0786A91E31'>

    • <optgroup id='0786A91E31'><strike id='0786A91E31'><sup id='0786A91E31'></sup></strike><code id='0786A91E31'></code></optgroup>
        1. <b id='0786A91E31'><label id='0786A91E31'><select id='0786A91E31'><dt id='0786A91E31'><span id='0786A91E31'></span></dt></select></label></b><u id='0786A91E31'></u>
          <i id='0786A91E31'><strike id='0786A91E31'><tt id='0786A91E31'><pre id='0786A91E31'></pre></tt></strike></i>

          Home / hotspot / knowledge

          knowledge


          knowledge

          author:hotspot    Page View:4878

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In